Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)
Lithium
45.37
0.15%
Gold
2,668.00
0.55%
Copper
4.14
(0.3%)
Oil
69.70
0.96%
Bitcoin
96,151.31
1.91%
FTSE 100
8,134.86
0.62%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,458.79
(0.18%)
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.27%
Hang Seng
19,601.11
(0.23%)

Clinuvel Pharmaceuticals Ltd

CUV

ASX

CLINUVEL (CUV) is a global specialty pharmaceutical group dedicated to improving the lives of patients with unmet medical needs. Their focus lies in developing and commercialising treatments for a range of conditions, including genetic, metabolic, systemic, and life-threatening acute disorders. Additionally, they work on creating innovative healthcare solutions specifically tailored to the needs of specialized populations.

Latest Posts

Line Chart with Gradient
Price
$13.160
-0.24 (-1.79%)
At Close 20/11 (AEST)
Related Companies
CANN GROUP LIMITED
$CAN
AROA BIOSURGERY LIMITED
$ARX
LTR PHARMA LIMITED
$LTP
RADIOPHARM THERANOSTICS LIMITED
$RAD
INVION LIMITED
$IVX

Leave a Comment on CUV


Comments for CUV

    Latest Posts

    clinuvel-pharmaceuticals-asx-cuv-in-discussions-to-expand-dosage-recommendations-cuv
    Health Care $CUV
    CLINUVEL Pharmaceuticals (ASX: $CUV) in discussions to expand dosage recommendationsEngaging with the EMA to increase SCENESSE® doses for EPP patients from four to six annually
    November 20, 2024
    clinuvel-pharmaceuticals-asx-cuv-shifts-focus-to-core-clinical-programs-cuv
    Health Care $CUV
    CLINUVEL Pharmaceuticals (ASX: $CUV) shifts focus to core clinical programsPrioritizing vitiligo, ACTH, and porphyrias to enhance clinical and commercial success
    November 18, 2024
    clinuvel-asx-cuv-files-new-drug-submission-for-scenesse-in-epp-cuv
    Health Care $CUV

    CLINUVEL (ASX: $CUV) files new drug submission for scenesse in epp

    Seeking approval for novel photoprotective therapy in Canada

    October 1, 2024
    clinuvel-asx-cuv-initiates-clinical-program-in-parkinsons-disease-cuv
    Health Care $CUV

    CLINUVEL (ASX: $CUV) initiates clinical program in parkinson's disease

    Program to evaluate afamelanotide as treatment in fair-skinned parkinson's patients

    June 18, 2024
    clinuvel-asx-cuv-announces-positive-results-for-scenesse-in-variegate-porphyria-patients-cuv
    Health Care $CUV

    CLINUVEL (ASX: $CUV) announces positive results for SCENESSE® in variegate porphyria patients

    Phase II study shows systemic photoprotection and improved quality of life for VP patients

    March 4, 2024

    CUV

    $CUV

    CLINUVEL Pharmaceuticals (ASX: $CUV) in discussions to expand dosage recommendations

    Engaging with the EMA to increase SCENESSE® doses for EPP patients from four to six annually

    CUV

    $CUV

    CLINUVEL Pharmaceuticals (ASX: $CUV) shifts focus to core clinical programs

    Prioritizing vitiligo, ACTH, and porphyrias to enhance clinical and commercial success

    CUV

    $CUV

    CLINUVEL (ASX: $CUV) files new drug submission for scenesse in epp

    Seeking approval for novel photoprotective therapy in Canada

    CUV

    $CUV

    CLINUVEL (ASX: $CUV) initiates clinical program in parkinson's disease

    Program to evaluate afamelanotide as treatment in fair-skinned parkinson's patients

    CUV

    $CUV

    CLINUVEL (ASX: $CUV) announces positive results for SCENESSE® in variegate porphyria patients

    Phase II study shows systemic photoprotection and improved quality of life for VP patients

    Related Companies
    BCAL DIAGNOSTICS LIMITED
    $BDX
    BOTANIX PHARMACEUTICALS LTD
    $BOT
    MAYNE PHARMA GROUP LIMITED
    $MYX
    VITA LIFE SCIENCES LIMITED..
    $VLS
    PARADIGM BIOPHARMACEUTICALS LIMITED..
    $PAR

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions